Interim results of the Oxford COVID-19 vaccine trials find that the vaccine protects against symptomatic disease in 70% of cases—with vaccine efficacy of 62% for those given two full doses, and of 90% in those given a half ...
Dec 08, 2020
0
30
Hopes of an effective vaccine against coronavirus becoming available rose again on Monday with AstraZeneca and Oxford University claiming success with their product, becoming the third team to do so.
Nov 23, 2020
0
0
Evidence suggesting an initial half dose of the vaccine being developed by drugs firm AstraZeneca and the University of Oxford is more effective than a full dose is counterintuitive, and even took the researchers by surprise.
Nov 23, 2020
0
9
Chemotherapy used to shrink a tumor before surgery, called neoadjuvant chemotherapy, is becoming more common in many cancers, including stage II and III rectal cancer. However, the chemotherapy regimens FOLFOX and CapeOx ...
Jan 30, 2020
0
3
Brigatinib is a next-generation ALK inhibitor that earned FDA approval in 2017 as a second-line therapy after treatment with crizotinib for ALK-positive non-small cell lung cancer. Recently, clinical trial results published ...
May 21, 2019
0
7
